Default company panoramic image
Logo

New Boston Medical, Inc.

This investment has a biotech ROI with none of the biotech risks. We present 5 companies that have exited in the CMO space over the past...

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Woburn, MA, USA
  • Currency USD
  • Founded January 2013
  • Employees 1
  • Website newbostonmedical.com

Company Summary

We present 5 exits that have taken place over the past few years as evidence of our ability to sell this company. NBM is a contract manufacturer in the biotech arena. There are 2 compelling reasons to invest: the expected ROI and our probability of success. We don't bear the risk of a single technology to be successful and we're not reliant upon the drug that we put into the vials to be approved by the FDA.

Team

  • Default avatar
    James Wilkie
    President & CEO

    Experienced in both small and multi-national companies, this is his 3rd startup. Pluromed’s COO until the sale of the company to Genzyme, a Sanofi company. Responsible for overall operation including product development, clinical affairs, RA/QA, mfg, distribution and admin. Prior to his experience at Pluromed, Mr. Wilkie was the head of engineering at MedChem Products until the sale to C. R. Bard.

Advisors

  • Default avatar
    Michelle Basil , Esq.
    Lawyer
    Unconfirmed

Previous Investors

  • Default avatar
    James Wilkie
    Unconfirmed
    Default avatar
    James Rolke
    Unconfirmed
    Default avatar
    Jean-Marie Vogel
    Unconfirmed